International Journal of Phytomedicine and Phytotherapy
Table 5 Experimental models for anti-fibrotic effects of Silybum marianum
From: The potential of silymarin for the treatment of hepatic disorders
Model | Silymarin doses | Effect |
|---|---|---|
CCl4 in transgenic mice | 200Â mg/kg | Ex vivo reduction of the genes Cox6a2, 7a1, Cox8b [113] |
CCl4 | 50 mg/kg | Anti-inflammatory effect, HSC activation, mast cell stabilization, TGFβ secretion[109] |
Thioacetamid | 150 mg/kg | Body weight ↓, serum cholesterol↓, TG↓, liver size ↑, ALT/AST↓,[110] |
CCl4 | 100 mg/kg i.p. (non therapeutic route) | Reduction of hepatic collagen content 18 %, Reduction hepatic fibrosis score 47 % [111] |
CCl4 | 20 or 100Â mg/kg | Reduction of inflammatory and fibrotic effects [131] |